In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp
- PMID: 18227181
- PMCID: PMC2292525
- DOI: 10.1128/AAC.01097-07
In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp
Abstract
The in vitro activity of amphotericin B in combination with micafungin was evaluated against 115 isolates representing seven species of Candida. Overall, the percentages of synergistic interactions were 50% and 20% when the MIC-2 (lowest drug concentration to cause a prominent reduction in growth) and MIC-0 (lowest drug concentration to cause 100% growth inhibition) end point criteria, respectively, were used. Antagonism was not observed. Some of the interactions were confirmed by time-kill assays.
Figures

Similar articles
-
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.Antimicrob Agents Chemother. 2006 Aug;50(8):2829-32. doi: 10.1128/AAC.00524-06. Antimicrob Agents Chemother. 2006. PMID: 16870779 Free PMC article.
-
In vitro combination therapy with isavuconazole against Candida spp.Med Mycol. 2017 Nov 1;55(8):859-868. doi: 10.1093/mmy/myx006. Med Mycol. 2017. PMID: 28204571
-
In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.Antimicrob Agents Chemother. 2005 Aug;49(8):3498-500. doi: 10.1128/AAC.49.8.3498-3500.2005. Antimicrob Agents Chemother. 2005. PMID: 16048969 Free PMC article.
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
[In vitro antifungal activity of micafungin].Rev Iberoam Micol. 2009 Mar 31;26(1):35-41. doi: 10.1016/S1130-1406(09)70006-3. Epub 2009 May 7. Rev Iberoam Micol. 2009. PMID: 19463275 Review. Spanish.
Cited by
-
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris.Pharmaceutics. 2021 Aug 25;13(9):1333. doi: 10.3390/pharmaceutics13091333. Pharmaceutics. 2021. PMID: 34575409 Free PMC article.
-
Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.Mycopathologia. 2013 Feb;175(1-2):129-34. doi: 10.1007/s11046-012-9591-2. Epub 2012 Oct 17. Mycopathologia. 2013. PMID: 23073824 Review.
-
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.J Fungi (Basel). 2021 Feb 4;7(2):113. doi: 10.3390/jof7020113. J Fungi (Basel). 2021. PMID: 33557026 Free PMC article. Review.
-
Novel method for evaluating in vitro activity of anidulafungin in combination with amphotericin B or azoles.J Clin Microbiol. 2012 Aug;50(8):2748-54. doi: 10.1128/JCM.00610-12. Epub 2012 Jun 12. J Clin Microbiol. 2012. PMID: 22692739 Free PMC article.
-
Antifungal combinations against simulated Candida albicans endocardial vegetations.Antimicrob Agents Chemother. 2009 Jun;53(6):2629-31. doi: 10.1128/AAC.01026-08. Epub 2009 Mar 23. Antimicrob Agents Chemother. 2009. PMID: 19307372 Free PMC article.
References
-
- Andes, D., and N. Safdar. 2005. Efficacy of micafungin for the treatment of candidemia. Eur. J. Clin. Microbiol. 24:662-664. - PubMed
-
- Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875. - PMC - PubMed
-
- Eliopoulos, G. M., and R. C. Moellering. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, MD.
-
- Reference deleted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous